Table 3.
Mean change from baseline from week 1 to week 12 in total lesion counts, inflammatory lesion counts, and non‐inflammatory lesion counts after CLNP/BPO 3% or ADA + CLNP treatment (ITT population)
| Total lesion count | Inflammatory lesion count | Non‐inflammatory lesion count | ||||
|---|---|---|---|---|---|---|
| CLNP/BPO 3% (n = 172) | ADA + CLNP (n = 177) | CLNP/BPO 3% (n = 172) | ADA + CLNP (n = 177) | CLNP/BPO 3% (n = 172) | ADA + CLNP (n = 177) | |
| Week 1 | ||||||
| n | 172 | 176 | 172 | 176 | 172 | 176 |
| Mean (SD) | −28.5 (25.64) | −28.0 (23.30) | −14.4 (11.12) | −12.4 (10.31) | −14.1 (20.35) | −15.5 (19.73) |
| Week 2 | ||||||
| n | 169 | 176 | 169 | 176 | 169 | 176 |
| Mean (SD) | −45.9 (27.08) | −39.3 (31.61) | −20.5 (11.20) | −17.3 (11.27) | −25.4 (22.18) | −22.0 (22.86) |
| Week 4 | ||||||
| n | 169 | 174 | 169 | 174 | 169 | 174 |
| Mean (SD) | −60.4 (31.52) | −54.7 (33.25) | −23.7 (10.85) | −20.5 (11.90) | −36.8 (26.99) | −34.2 (26.91) |
| Week 8 | ||||||
| n | 167 | 172 | 167 | 172 | 167 | 172 |
| Mean (SD) | −70.7 (33.88) | −68.8 (34.87) | −25.5 (11.11) | −23.1 (12.08) | −45.2 (28.43) | −45.7 (29.19) |
| Week 12 | ||||||
| n | 164 | 169 | 164 | 169 | 164 | 169 |
| Mean (SD) | −80.7 (34.03) | −78.1 (36.33) | −27.2 (11.02) | −25.6 (11.71) | −53.5 (28.40) | −52.5 (31.46) |
ADA, adapalene; BPO, benzoyl peroxide; CLNP, clindamycin phosphate; ITT, intent‐to‐treat; SD, standard deviation.